Dr. Streicher is interested in understanding the molecular signal transduction cascades downstream of the opioid receptors. His research program focuses on finding new signaling regulators of the opioid receptors, determining their molecular mechanisms, and then determining how these molecular mechanisms result in changes to opioid-induced analgesia and side effects in different pain states. He further uses this information to create novel drug discovery strategies to create new opioid drugs without the side effect drawbacks of current drugs, like addiction. His research approaches encompass the creation of pain states such as post-surgical pain and the measurement of opioid analgesia in these pain states, combined with state-of-the-art approaches to modulate novel signaling regulators in mice including CRISPR/Cas9 in the brain and spinal cord. He also screens drugs in medium- to high-throughput formats in cell models to find and develop new analgesic drugs.
John M. Streicher, PhD
Assistant Professor, Neuroscience - GIDP
Member of the Graduate Faculty
Contact InformationOffice: Room 563, Life Sciences North
Building: Life Sciences North
Phone: (520) 626-7495
- BS: George Fox University, 1999
- MS: Oregon Health and Science University, 2002
- PhD: University of California – Los Angeles, 2009
The natural product argentatin C attenuates postoperative pain via inhibition of voltage-gated sodium and T-type voltage-gated calcium channels.
Discovery of κ Opioid Receptor (KOR)-Selective d-Tetrapeptides with Improved Antinociceptive Effect after Peripheral Administration.
Extracellular Alterations in pH and K+ Modify the Murine Brain Endothelial Cell Total and Phospho-Proteome.
Age-Induced Changes in μ-Opioid Receptor Signaling in the Midbrain Periaqueductal Gray of Male and Female Rats.
Heat shock protein 90 inhibitors block the antinociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models.
A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.
Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain.
Fluorescent-labeled bioconjugates of the opioid peptides biphalin and DPDPE incorporating fluorescein-maleimide linkers.
Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice.
17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.
The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence.
Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy.
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.
Proteasome-dependent degradation of cytochromes P450 2E1 and 2B1 expressed in tetracycline-regulated HeLa cells.